Adult Stem Cell Therapy Today: The Future is Here
Leslie Miller, M.D., F.A.C.C. and Okyanos Chief Science Officer, gives an overview of the benefits of adult stem cell therapy for severe heart disease patients. Okyanos provides Cardiac Cell...

By: Okyanos Heart Institute

Original post:
Adult Stem Cell Therapy Today: The Future is Here - Video

China tests stem cell therapy for heart disease
Monday marks World Heart Day. One of the most serious conditions is Chronic Heart Disease. It has no cure to date, but in China, scientists are hoping to find one, using stem-cell technology.

By: CCTV America

Read this article:
China tests stem cell therapy for heart disease - Video

Edgar Irastorza was just 31 when his heart stopped beating in October 2008.

A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wifes third pregnancy progressed. I kind of got pregnant, too, he said.

During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flat-lined.

He survived the heart attack, but the scar tissue that resulted cut his hearts pumping ability by a third. He couldnt pick up his children. He couldnt dance. He fell asleep every night wondering if he would wake up in the morning.

Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart.

I just trusted my doctors and the science behind it, and said, This is my only chance, he said recently.

Over the last five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.

Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimers, and to grow new parts to treat conditions like spinal cord injuries.

Progress has been slow. The Michael J. Fox Foundation for Parkinsons Research, an early supporter of stem cell research, pulled its financial backing two years ago, saying that it preferred to invest in research that was closer to providing immediate help for Parkinsons disease patients.

But researchers have been slowly learning how to best use stem cells, what types to use and how to deliver them to the body findings that arent singularly transformational, but progressive and pragmatic.

Follow this link:
Stem cell therapies making slow but promising progress

Stem Cell Therapy in Muscular Dystrophy - Man
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read more here:
Stem Cell Therapy in Muscular Dystrophy - Man - Video

Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 13-03-2014
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Link:
Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 13-03-2014 - Video

Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read the original post:
Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014 - Video

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

Continue reading here:
Germantown

St. Petersburg, FL (PRWEB) September 16, 2014

Aging skin inevitably wrinkles, thins and sags.

The main internal reason for this is loss of collagen production. By age 60, skin has 45% less collagen than it did when young due to this slow down. Collagen holds up skin structure.

In order to maintain healthy, beautiful skin, collagen production should be boosted. There are several ways to do this, but the relatively new scientific approach is through use of stem cells (non-embryonic).

"The cost is higher than other types of serums, but you also get what you pay for," says Kathy Heshelow, founder of Sublime Beauty."Stem cell serums rich in growth factors and human fibroblast conditioned media bring back firmer, younger and smoother skin."

Scientists have used these ingredients in wound repair with great success, and the crossover to skin care seemed natural. TGF-b or Transforming Growth Factor-beta is considered to be one of the most important growth factors to stimulate collagen production, promote synthesis and inhibit thinning of skin.

The Sublime Beauty serum, Cell Renewal | Fibroblast Serum, contains these very growth factors. A brochure explaining more about the ingredients is available on the product page of the company webstore.

Similar serums on the market are far more expensive the one offered by Sublime Beauty. Take 25% Off the stem cell serum at Amazon with coupon code FIBRO52V now.

ABOUT: Sublime Beauty is a quality skincare company that focuses on products to Age Younger. Ingredients help to boost collagen, hydrate, relax wrinkles and improve skin. A niche includes healthy Skin Brushes. The company webstore offers free standard shipping and a VIP Club. Sign up for Secret Sales on the site. Products also available on Amazon.

See the article here:
A Superior Way to Make Skin Younger and Assure Continual Collagen Production, from Sublime Beauty

Stem cells broke into the public consciousness in the early 1990s, but progress has been slow. Photo: Bloomberg

Edgar Irastorza was just 31 when his heart stopped beating in October 2008.

A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said.

During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined.

He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He couldn't dance. He fell asleep every night wondering if he would wake up in the morning.

Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart.

"I just trusted my doctors and the science behind it, and said, 'This is my only chance,'" he said recently.

Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.

Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimer's, and to grow new parts to treat conditions like spinal cord injuries.

Progress has been slow. The Michael J. Fox Foundation for Parkinson's Research, an early supporter of stem cell research, pulled its financial backing two years ago, saying that it preferred to invest in research that was closer to providing immediate help for Parkinson's disease patients.

Go here to see the original:
Trials and tribulations of stem cell therapy

Surgeons implanted retinal tissue created after reverting the patient's own cells to a "pluripotent" state

Researchers were able to grow sheets of retinal tissue from induced pluripotent stem cells, and have now implanted them for the first time in a patient. Credit: RIKEN/Foundation for Biomedical Research and Innovation

A Japanese woman in her 70s is the world's first recipient of cells derived from induced pluripotent stem cells, a technology that has created great expectations since it could offer the same advantages as embryo-derived cells but without some of the controversial aspects and safety concerns.

In a two-hour procedure starting at 14:20 local time today, a team of three eye specialists lead by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, transplanted a 1.3 by 3.0 millimeter sheet of retinal pigment epithelium cells into an eye of the Hyogo prefecture resident, who suffers from age-related macular degeneration.

The procedure took place at the Institute of Biomedical Research and Innovation Hospital, next to the RIKEN Center for Developmental Biology (CDB) where ophthalmologist Masayo Takahashi had developed and tested the epithelium sheets. She derived them from the patient's skin cells, after producing induced pluripotent stem (iPS) cells and then getting them to differentiate into retinal cells.

Afterwards, the patient experienced no effusive bleeding or other serious problems, RIKEN has reported.

The patient took on all the risk that go with the treatment as well as the surgery, Kurimoto said in a statement released by RIKEN. I have deep respect for bravery she showed in resolving to go through with it.

He hit a somber note in thankingYoshiki Sasai, a CDB researcher who recenty committed suicide. This project could not have existed without the late Yoshiki Sasais research, which led the way to differentiating retinal tissue from stem cells.

Kurimoto also thanked Shinya Yamanaka, a stem-cell scientist at Kyoto University without whose discovery of iPS cells, this clinical research would not be possible. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for that work.

Kurimoto performed the procedure a mere four days after a health-ministry committee gave Takahashi clearance for the human trials (see 'Next-generation stem cells cleared for human trial').

Read more:
Next-Generation Stem Cells Transplanted in Human for the First Time

TIME Health medicine Woman Receives First Stem Cell Therapy Using Her Own Skin Cells A Japanese woman is the first to receive retinal cells made from her own skin cells

Researchers at the RIKEN Center for Developmental Biology in Japan surgically transplanted a sheet of retinal pigment cells into the eye of a 70-year old woman on Friday.

The cells are the first induced pluripotent stem cells, or iPS cells, given to a human patient. They were made by Masayo Takahashi, who grew them from the patients own skin cells, which were treated with four genetic factors to revert back to an embryonic-like state. Takahashi then soaked the cells with the appropriate growth factors and other compounds so they developed into retinal pigment cells.

The patient was losing her sight due to macular degeneration, because her retinal pigment endothelial cells were damaged by an overgrowth of blood vessels. Replacing them with a new population of cells can restore her sight.

MORE: Stem-Cell Research: The Quest Resumes

Stem cell scientists are starting to test their treatments in eye-related diseases, because parts of the eye are protected from the bodys immune system, which could recognize the introduced cells as foreign and destroy them. Thats not a problem with the iPS cells, since they are made from the patients own skin cells, but its an added safety net to ensure that the therapy is safe and hopefully effective.

Because iPS cells are genetically treated to erase their skin cell development and revert them back to an embryonic-like state when they can become any type of cell, there are still concerns about their safety when transplanted into patients. The U.S. Food and Drug Administration has not yet approved a trial involving iPS cells so far, only stem cells made from excess IVF embryos have been approved for treating macular degeneration. A 19-member committee of the Japanese ministry of health approved the experimental procedure four days ago, according to Nature, after Takahashi made her case, with the help of Dr. Shinya Yamanaka of Kyoto University, who shared the 2012 Nobel Prize for discovering iPS cells.

MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions like Alzheimers

Japans stem cell scientists are hoping the surgery is a success; the field has been struggling since a well-publicized paper about a new way to make iPS cells was retracted amid allegations of fraud.

Its not known whether the cells will continue to grow and form abnormal tumors, or whether they will migrate to other parts of the body. But now that the first patient has received them, those questions and more, about the effectiveness of stem cell therapy might be answered soon.

Continued here:
Woman Receives First Stem Cell Therapy Using Her Own Skin Cells

Human trials on the effectiveness of using adult stem cells in the fight against cornea transplant rejection could be under way within the next five years.

Corneal eye disease is the fourth most common cause of blindness in the world and affects more than 10 million people worldwide. New research from NUI Galway has found that transplant rejection rates could be reduced to as low as 10% by administering a stem cell grown from the bone marrow of adult donors.

Although 100,000 people worldwide undergo cornea transplants each year, about 30% are unsuccessful due to rejection by the patients own immune system.

An unhealthy cornea affects vision by scattering or distorting light and causing glare and blurred vision.

Corneal transplants are the most widely used treatments where the diseased or scarred cornea is replaced with healthy tissue from an organ donor.

Researchers from NUI Galways Regenerative Medicine Institute previously found that mesenchymal stem cells (MSC) release chemicals capable of adjusting the immune system balance in the body.

The cells can be readily obtained and grown from the bone marrow of adult donors and the finding led them to study their usefulness in combating cornea transplant rejection.

The teams lead scientist, Dr Oliver Treacy, said the model system they developed led to an increase in cells called regulatory T-cells, which dampen down inflammation, and a decrease in the number of natural killer cells, key players in the rejection process.

Consultant ophthalmologist at Galway University Hospital, Gerry Fahy, who was involved in the study, said corneal transplant rejection could result in blindness and was not uncommon in high-risk patients.

This important research presents a potentially new avenue of treatment to prevent transplant rejection and save vision in this vulnerable group of patients, said Mr Fahy.

Go here to see the original:
Stem cells could cut high rate of cornea transplant rejection

FATHER-OF-TWO Johnny Pearson's life was saved when a stranger donated stem cells. The pair became friends and raised thousands for charity by running in the London Marathon together. By health reporter Kate Liptrot.

EARLIER this year Johnny Pearson became the first person to run the London Marathon alongside the unrelated stem cell donor who had saved his life.

The 44-year-old was diagnosed with acute myeloid leukaemia in 2010 and often thought of the stranger had been who allowed him to have a bone marrow transplant two years later.

Earlier this year he met 23-year-old donor Sean Hagan for the first time - and weeks after meeting they ran the London marathon to raise money and awareness for the Anthony Nolan Bone Marrow Trust.

The wine trader from Thorpe Underwood was first diagnosed with the aggressive form of cancer in September 2010 when he had been to see the doctor after feeling slightly under the weather and the doctor had done a blood test just to make sure.

He was driving home from work when he received a phone call from the doctor to say that something was seriously wrong and he needed to turn around and go to York Hospital.

Johnny started chemotherapy days later and after six months of gruelling chemotherapy was finally in remission and returned home to his wife, Sarah, and young boys, Jack, now 12, and Archie, now ten.

But in July 2011, Johnny received the devastating news that leukaemia had returned. This time, Johnny would need a bone marrow transplant to survive and the race was on to find a matching donor.

It was the worst possible news and I thought that my life was over," Johnny said, "The last hope was a bone marrow transplant and I remember waiting to hear if there was a matching donor.

"It was a very difficult time for me and my family as we knew that my life was in someone elses hands. After what seemed like the longest few months of my life, my doctor sat me down and told me that Anthony Nolan had found a donor.

Go here to read the rest:
Running with a real lifesaver

Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-much-does-stem-cell-therapy-cost/ Find out about how much stem cell therapy will cost you...

By: Thanyapura Health Centre

More:
Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost - Video

A new research has revealed that three major pigment cell types i.e. black cells, reflective silvery cells, and yellow cells helped in forming the stripes on zebrafish.

The research conducted by Max Planck Institute for Developmental Biology in Tubingen showed that the yellow cells undergo dramatic changes in cell shape to tint the stripe pattern of zebrafish.

First author Prateek Mahalwar said that they were surprised to observe such cell behaviours, which were totally unexpected color pattern formation.

The study revealed that the three cell types reached the skin by completely different routes. A pluripotent cell population situated at the dorsal side of the embryo gave rise to larval yellow cells, which covered the skin of the embryo and began to multiply at the onset of metamorphosis when the fish was about two to three weeks old.

However, the black and silvery cells came from a small set of stem cells, which is associated with nerve nodes located close to the spinal cord in each segment.

Brigitte Walderich, a co-author of the Science paper, explained that they were surprised to discover that the small clusters of fluorescently labelled cells in the embryo, which could be followed during larval and juvenile stages to unravel growth and behaviour of the yellow cells, divided and multiplied as differentiated cells to cover the skin of the fish before the silvery and black cells arrive to form the stripes.

The study is published in journal Science.

(Posted on 29-08-2014)

Information on States of India:

Andaman Nicobar | Andhra Pradesh | Assam | Bihar | Chandigarh | Chhattisgarh | Dadar Nagar Haveli | Daman Diu | Delhi | Goa | Gujarat | Haryana | Himachal Pradesh | Jammu Kashmir | Jharkhand | Karnataka | Kerala | Lakshadweep | Madhya Pradesh | Maharashtra | Manipur | Meghalaya | Mizoram | Nagaland | Orissa | Pondicherry | Punjab | Rajasthan | Sikkim | Tamil Nadu | Tripura | Uttar Pradesh | Uttaranchal | West Bengal

View post:
How zebrafish forms its stripes revealed

CARLSBAD, CA--(Marketwired - August 28, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.

Rodman and Renshaw 16th Annual Global Investment Conference:

Date:Wednesday, September 10, 2014 Time:11:40 a.m. ET Location:New York Palace Hotel, New York, NY Room:Kennedy I

Conference details:http://www.meetmax.com//sched/event_23003/~public/conference_home.html?event_id=23003

AEGIS CAPITAL Corp. 2014 Healthcare and Technology Conference:Date:Thursday, September 11, 2014 Time:10:45 a.m. PT Location:The Encore at Wynn, Las Vegas, NV

Conference details:http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

See more here:
International Stem Cell Corporation to Present at Two Upcoming Investment Conferences

Jilly #39;s Miracle post stem cell therapy at Australind Veterinary Hospital
Jilly pain free following stem cell therapy at Australind Veterinary Hospital.

By: AustralindVet

Read more:
Jilly's Miracle post stem cell therapy at Australind Veterinary Hospital - Video

Stem Cell Therapy as a Treatment Option for Osteoarthritis
Dr. Frank Garcia, board certified orthopedic surgeon with The San Antonio Orthopaedic Group, discusses the use of stem cell therapy in the treatment of osteo...

By: The San Antonio Orthopaedic Group

Continued here:
Stem Cell Therapy as a Treatment Option for Osteoarthritis - Video

By RTT News, August 26, 2014, 06:00:00 PM EDT

(RTTNews.com) - GlaxoSmithKline plc (GSK, GSK.L) said Tuesday the U.S. Food and Drug Administration approved a supplemental New Drug Application for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.

Severe aplastic anaemia, or SAA, is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets. Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.1

"FDA approval of Promacta addresses a significant treatment need for this very rare but serious blood disorder in those who have failed current treatment options," said Paolo Paoletti, president of Oncology, GSK.

Promacta gained Breakthrough Therapy designation status from the FDA in January 2014 and Priority Review in April 2014. Today's approval by the FDA is based on results from an investigator-sponsored Phase II study conducted by the National Heart, Lung and Blood Institute at the National Institutes of Health.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Go here to read the rest:
GSK: FDA OKs Promacta SNDA In Patients With Aplastic Anaemia

Why not embryonic stem cell
Why not embryonic stem cell ? In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Stem Cell Therapy...

By: Neurogen Brain and Spine Institute

Here is the original post:
Why not embryonic stem cell - Video